Literature DB >> 6941958

High performance liquid chromatographic determination of aclacinomycin a and its related compounds. II. Reverse phase HPLC determination of aclacinomycin A and its metabolites in biological fluids using fluorescence detection.

T Ogasawara, Y Masuda, S Goto, S Mori, T Oki.   

Abstract

A sensitive, simple and selective reverse phase high performance liquid chromatographic method was applied to the determination of aclacinomycin A (ACM) and its metabolites in plasma. The chromatography was performed on a microparticulate phenethyl derivative of silica using a mobile phase of acetonitrile-0.03 M ammonium formate buffer (pH 5.0), (50:50, v/v) and monitoring with fluorescence detector (excitation 435 nm-emission 505 nm). High reproducibility and linear calibration curves were obtained from 20 ng/ml to 100 ng/ml of ACM and its metabolites in plasma by use of internal standard methods.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6941958     DOI: 10.7164/antibiotics.34.52

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  6 in total

1.  Plasma kinetics of aclacinomycin A and its major metabolites in man.

Authors:  M J Egorin; D Van Echo; B M Fox; M Whitacre; N R Bachur
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 2.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

3.  Phase I and pharmacokinetic study of high volume intraperitoneal aclacinomycin-A (Aclarubicin).

Authors:  I G Kerr; S Archer; C DeAngelis; S Farrell; S Hanna; J McKee
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

4.  Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study.

Authors:  C Karanes; J D Young; M K Samson; L B Smith; L A Franco; L H Baker
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

5.  Sensitive enzyme immunoassay for the quantification of aclacinomycin A using beta-D-galactosidase as a label.

Authors:  M Sohda; K Fujiwara; H Saikusa; T Kitagawa; N Nakamura; K Hara; H Tone
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Role of the aclacinomycin A--doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells.

Authors:  J M Millot; T D Rasoanaivo; H Morjani; M Manfait
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.